Workflow
ESSA Bancorp(ESSA)
icon
Search documents
ESSA Bancorp(ESSA) - 2024 Q3 - Quarterly Report
2024-08-13 20:51
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-----------------------|-------------------|-------|----------------|--------------------------|----------------|----------------- ...
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
Prnewswire· 2024-08-05 11:00
On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected ...
ESSA Bancorp(ESSA) - 2024 Q3 - Quarterly Results
2024-07-25 16:01
• Total yield on average interest earning assets increased to 5.02% for the quarter ended June 30, 2024, from 4.60% for the quarter ended June 30, 2023. • Total cost of interest-bearing liabilities increased to 2.80% for the quarter ended June 30, 2024, from 1.75% for the quarter ended June 30, 2023. • The provision for credit losses for the three months ended June 30, 2024, was a release of $347,000 compared to a provision of $150,000 for the three months ended June 30, 2023. The provision for the nine-mon ...
Essa Bancorp (ESSA) Lags Q3 Earnings and Revenue Estimates
ZACKS· 2024-07-24 23:00
Essa Bancorp, which belongs to the Zacks Financial - Savings and Loan industry, posted revenues of $16.28 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 5.82%. This compares to year-ago revenues of $17.18 million. The company has topped consensus revenue estimates two times over the last four quarters. This quarterly report represents an earnings surprise of -8.89%. A quarter ago, it was expected that this bank would post earnings of $0.35 per share when it actually produce ...
Essa Bancorp (ESSA) Moves 5.4% Higher: Will This Strength Last?
ZACKS· 2024-07-17 12:50
Essa Bancorp (ESSA) shares rallied 5.4% in the last trading session to close at $19.50. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.5% gain over the past four weeks. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements ...
ESSA Pharma to Present at the JonesHealthcare Seaside Summit
Prnewswire· 2024-07-08 20:05
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will present at the JonesHealthcare Seaside Summit on Monday, July 15, 2024 at 11:00 a.m. PT. David R. Parkinson, President and Chief Executive Officer, will host the presentation and will also participate in a panel discussion ...
ESSA Pharma to Present at the Jefferies Global Healthcare Conference
Prnewswire· 2024-05-30 12:00
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York. David. R. Parkinson, President, and Chief Executive Officer and David S. Wood, Chief Financial Officer, wil ...
ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer
seekingalpha.com· 2024-05-29 21:44
Business Overview EPIX is a clinical-stage pharmaceutical company focused on developing therapies for prostate cancer. It was founded in 2009 and operates in Houston, San Francisco, and Vancouver. Today, EPIX's science focuses on therapies designed to disrupt the androgen receptor [AR] using N-terminal Domain [NTD] inhibitors called Anitens to inhibit cancer growth. Prostate cancer is the most common cancer in men in the U.S. and the second cause of male cancer deaths. About 1 in 8 men will be diagnosed wit ...
ESSA Bancorp(ESSA) - 2024 Q2 - Quarterly Report
2024-05-13 19:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to __________ Commission File No. 001-33384 ESSA Bancorp, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 20-8023072 (State or other jurisdictio ...
ESSA Bancorp(ESSA) - 2024 Q2 - Quarterly Results
2024-04-25 20:17
Exhibit 99.1 ESSA Bancorp, Inc. Announces Fiscal Second Quarter and Fiscal First Half 2024 Financial Results Stroudsburg, PA. – April 24, 2024 — ESSA Bancorp, Inc. (the "Company") (NASDAQ:ESSA), the holding company for ESSA Bank & Trust (the "Bank"), a $2.2 billion asset financial institution providing full service commercial and retail banking, financial, and investment services in eastern Pennsylvania, today announced financial results for the fiscal second quarter and fiscal first half periods ended Marc ...